Capital Grand Est

SUPERBRANCHE is a biotechnology company focused on the early detection and treatment of metastases using advanced nanotechnology. The company develops therapeutic and diagnostic applications that aim to enhance accessibility and facilitate the timely identification of tumors. Its innovative platform incorporates targeted diagnostic and image-guided therapy nanomaterials, grounded in proprietary technology. This approach enables healthcare providers to detect and address metastases earlier, ultimately improving patient outcomes.

Keey Aerogel specializes in the production of silica aerogel derived from construction waste using a closed-loop process that recycles carbon dioxide and ethanol. The company focuses on the valorization of silica-containing construction and demolition materials, transforming them into high-value aerogel products. These nanoporous materials are designed to enhance energy efficiency in the construction and refurbishment of buildings, as well as for various industrial applications. By leveraging waste materials, Keey Aerogel aims to contribute to sustainable practices while providing effective thermal insulation solutions in ambient conditions.

Cixten is a company that recycles low temperature waste heat into other energy vectors by leveraging the features of supercritical CO2.

Sirfull is a software company based in Schiltigheim, France, that specializes in developing cloud-based solutions for welding quality and equipment life cycle management. The company offers VDB, a welding quality management software designed to oversee welding quality control and technical documentation, and IRM, an equipment inspection software that facilitates the inspection, monitoring, and risk management of industrial equipment. These solutions help centralize processes on a collaborative platform, thereby enhancing operational efficiency and reducing maintenance costs for clients in various sectors, including oil and gas, nuclear energy, and pharmaceuticals. Additionally, Sirfull provides technical outsourcing and integration services, with its software available as a Software-as-a-Service or for PC/server installation. The company has sales offices in Strasbourg and Lyon, serving manufacturers and operating companies looking to optimize their business processes through digital manufacturing.

RDS is a healthcare technology startup focused on remote patient monitoring solutions, with its flagship product, MultiSense®. This innovative platform enables healthcare professionals to continuously track patients' physiological parameters both in hospitals and at home, promoting enhanced patient pathways and care efficiencies. MultiSense® combines a wearable monitor that captures high-accuracy data with a cloud platform that transforms this information into actionable clinical insights. Aimed primarily at hospitals and healthcare institutions, the solution facilitates early hospital discharge and helps reduce hospital stays, thereby contributing to significant healthcare savings. MultiSense® has received CE marking and is available for sale in several European countries, generating recurring revenues through a fee-for-service model. The product has garnered multiple awards and support from a community of clinicians, while RDS also offers training and support to help healthcare systems effectively utilize the technology. The company is driven by a team of experienced professionals with extensive backgrounds in technology, healthcare, and biotech.

Exeliom is a clinical-stage biopharmaceutical company based in Dijon, France, focused on developing innovative microbial therapies that utilize commensal bacteria as therapeutic agents. Founded in 2016, Exeliom aims to unlock the therapeutic potential of gut microbiota to enhance health and longevity. The company specializes in creating a new class of medicines known as Live Biotherapeutics, which are designed to deliver microbiome-based immunotherapy for conditions such as inflammatory bowel diseases and cancer, with an initial focus on Crohn's Disease. By harnessing the role of microbiota in the immune system, Exeliom strives to provide patients with advanced treatments that improve their quality of life.

Braintale is a Paris-based company founded in 2018 that develops and distributes diagnostic and prognostic tools specifically designed for brain-injured patients. Its platform focuses on analyzing MRI reports to assist healthcare professionals in effectively diagnosing patients who are in comas due to severe traumatic brain injuries, cardiac arrests, or hemorrhagic strokes. With over 15 years of clinical development backing its products, Braintale aims to meet the expectations of both healthcare professionals and patients by providing accessible and effective tools for prognosis and diagnosis in critical care settings.

Odimma is a biotech company specializing in precision medicine aimed at developing personalized cancer immunotherapy solutions. The company has created an innovative immunotherapy drug that harnesses a unique platform, integrating three specific immune components designed to work together with the patient's immune system. When administered, this approach aims to induce and enhance immune responses, providing patients with the potential to eliminate tumors while minimizing adverse side effects. Through its focus on personalized treatment strategies, Odimma seeks to improve outcomes for cancer patients by tailoring therapies to individual needs.

Miraxess specializes in transforming smartphones into functional laptops through its innovative product, the Mirabook. Recognizing the growing reliance on smartphones for personal and professional tasks, the company has developed a plug-in device that enhances the capabilities of mobile phones, effectively creating a full-fledged laptop experience. This solution aims to improve productivity and comfort, catering to the needs of users for both work and entertainment. By leveraging the existing power of smartphones, Miraxess offers a practical convergence of mobile and computing technology.